Courthouse News
A dispute over a U.N. vote on cannabis ended Tuesday with a sharp warning from Europe’s highest court: Once the EU settles on a common position abroad, member states cannot go off script.
That message was directed squarely at Hungary, after Budapest voted against a jointly agreed EU line at the United Nations Commission on Narcotic Drugs, the body that sets global rules on how drugs are classified and controlled under international treaties.
Although the EU itself does not hold a formal vote in the U.N. commission, the Court of Justice of the European Union said member states remain bound to defend a common EU position in international forums. By breaking ranks, Hungary crossed a line that cuts to the core of how the bloc speaks and acts on the world stage.
As the judges wrote, “Such conduct undermined the effectiveness of the international action of the European Union and the latter’s credibility and reputation on the international scene.”
By its application, the European Commission claims that the Court should:
– declare that, by failing to follow the European Union’s position at the reconvened sixty-third session of the Commission on Narcotic Drugs, on the amendment of the scheduling of cannabis and cannabis-related substances, Hungary (i) failed to fulfil its obligations under Council Decision (EU) 2021/3 of 23 November 2020 on the position to be taken, on behalf of the European Union, at the reconvened sixty-third session of the Commission on Narcotic Drugs, on the scheduling of cannabis and cannabis-related substances under the Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol, and the Convention on Psychotropic Substances of 1971 (OJ 2021 L 4, p. 1), which is binding on Hungary under Article 218(9) TFEU, read in conjunction with the fourth paragraph of Article 288 TFEU; (ii) infringed the European Union’s exclusive external competence provided for in Article 3(2) TFEU; and (iii) acted in breach of the principle of sincere cooperation enshrined in Article 4(3) TEU; and
– order Hungary to pay the costs.
The dispute traces back to a December 2020 vote, when governments at the U.N. commission were asked whether to ease the strictest international controls on cannabis, following scientific recommendations from the World Health Organization. In the lead up, EU capitals spent months coordinating and ultimately fixed a shared stance through a formal EU decision.
Hungary nonetheless departed from that position, voting against key elements of the agreed EU line and publicly spelling out its objections.
That, the judges found, was decisive. Once a binding EU position is adopted, national governments are expected to uphold it.
Domestically, Hungary has taken a hard line on drugs, folding cannabis into a broader political narrative about public order, family values and state control. Officials have warned about rising use, especially among young people, and have argued that easing international classifications would send the wrong signal at home. At the U.N., Budapest leaned heavily on those concerns, saying changes risked normalizing a drug it sees as a genuine public health threat.
From the EU’s perspective, the dispute was not about softening drug policy but about updating technical classifications to reflect current medical science.
What set the controversy in motion was a basic question with far-reaching consequences: How cannabis should be treated under international drug law. Under the U.N.’s 1961 Single Convention on Narcotic Drugs, substances are divided into four schedules, with Schedule IV reserved for those seen as especially harmful and offering little or no medical value. For decades, cannabis sat in that most restrictive category, grouped alongside heroin.
That assessment came under pressure as science and medical practice evolved. In 2019, the World Health Organization urged governments to rethink cannabis’ status.
Its main recommendation was modest but telling. Cannabis and cannabis resin — the concentrated substances extracted from the cannabis plant — would be removed from Schedule IV while remaining under control in Schedule I, recognizing accepted medical uses without legalizing the drug or dismantling international oversight.
After months of internal debate, EU governments locked in their response. By a qualified majority, they adopted a binding decision instructing member states represented on the U.N. drugs commission to support the reclassification and a narrow set of technical adjustments.
When the matter reached the U.N. vote, the commission narrowly endorsed the WHO recommendation. Hungary broke ranks. It voted against the reclassification and argued publicly that the changes sent the wrong signal domestically, pointing to rising cannabis use and public health concerns.
Brussels treated the move as more than a policy disagreement and took Hungary to court, arguing it breached EU law.
The judges agreed. Because changes to international drug schedules flow straight into EU law — including rules on criminal penalties for drug trafficking — the court said the bloc alone has the authority to set the position to be defended internationally.
Hungary’s fallback argument was that the EU decision itself was unlawful, arguing that Brussels overstepped its powers and could not bind member states in a forum where the EU has no vote.
The court was unmoved. Judges said a government cannot ignore a binding EU act on the international stage and then, only when it is called out, claim the act never should have applied. If Hungary believed the decision was legally flawed, the court stressed, the place to fight that battle was through the EU’s legal channels before defying it, not afterward.
Jed Odermatt, a reader in public international law at City St. George’s, University of London, said the ruling underscores a core principle of EU external relations: unity abroad. Once the EU has agreed on a position, he said, international action is meant to follow a single, coordinated line.
Merijn Chamon, a professor of EU law at the Vrije Universiteit Brussel, focused on what that means in practice. The dispute, he said, is less about cannabis than about institutional discipline. A common position, once adopted, binds governments in concrete ways, leaving no legal space to improvise internationally, even under domestic political pressure.
As he put it, when a state disagrees, “it must still defend that position in the international body concerned, and cannot in any event unilaterally decide to present a deviating position on its own behalf.”
That tension between EU coordination and national politics was particularly visible in Hungary’s stance — and judges made clear it was not a one-off.
In recent years, Budapest has repeatedly clashed with EU institutions over how much room member states have to go their own way once a common line is set, from rule-of-law disputes to migration and foreign policy coordination. Against that backdrop, the court treated the cannabis vote as another test of how far a member state can push back after a collective EU decision.
Judges stressed that removing cannabis from Schedule IV did not legalize the drug or loosen international controls. Cannabis would remain regulated under Schedule I, and member states would retain full authority to enforce strict national rules. The aim, the court made clear, was alignment with medical evidence, not a shift toward permissiveness.
Peter Van Elsuwege, professor of EU law and at Ghent University, said the judgment fits squarely within existing EU case law on sincere cooperation.
In his view, Hungary’s vote was a textbook example of a member state undermining the unity of EU external action. He highlighted the court’s warning that treaty obligations cut both ways: Enjoying the benefits of membership also means respecting common rules abroad.
From a drug policy perspective, however, the ruling also underlines the constraints built into the EU framework.
Ann Fordham, executive director of the International Drug Policy Consortium, warned that the court’s approach treats changes to U.N. drug schedules as a matter of exclusive EU competence, tightening legal limits on how far member states can shape their own cannabis policies without a common EU position. Those limits, she said, persist even as scientific evidence and political debates continue to evolve.
As Fordham put it, “punitive drug policies in the EU and elsewhere have utterly failed to reduce the scale of the illegal drug market,” while instead fueling “countless human rights abuses and a preventable public health crisis.”
The court did not engage with those broader policy questions. The court flatly rejected Hungary’s defenses and came down on the side of the commission, ordering Budapest to pay the costs. With no appeal available, the case is now closed.
The ruling locks in the commission’s view that Hungary breached EU law, giving Brussels firmer footing to demand compliance in future global votes where a common EU position has been agreed.
The European Commission and the Hungarian government did not immediately respond to requests for comment.
Courthouse News reporter Eunseo Hong is based in the Netherlands.
Hungary can’t pick and choose EU positions abroad, top court says after cannabis vote
Also IDPC
